88Q Stock Overview
Engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
4basebio PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£14.30 |
| 52 Week High | UK£21.20 |
| 52 Week Low | UK£7.50 |
| Beta | 1.13 |
| 1 Month Change | -8.33% |
| 3 Month Change | -15.38% |
| 1 Year Change | 78.75% |
| 3 Year Change | 130.65% |
| 5 Year Change | n/a |
| Change since IPO | 76.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 88Q | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.7% | -3.5% | -2.0% |
| 1Y | 78.8% | -14.7% | 6.9% |
Return vs Industry: 88Q exceeded the German Biotechs industry which returned -14.7% over the past year.
Return vs Market: 88Q exceeded the German Market which returned 6.9% over the past year.
Price Volatility
| 88Q volatility | |
|---|---|
| 88Q Average Weekly Movement | 2.1% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 88Q has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 88Q's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 101 | Heikki Lanckriet | www.4basebio.com |
4basebio PLC engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company offers AVV and Lentivirus manufacturing services for use in gene therapies and vaccines. It also offers access to its targeted non-viral delivery platform, Hermes.
4basebio PLC Fundamentals Summary
| 88Q fundamental statistics | |
|---|---|
| Market cap | €182.87m |
| Earnings (TTM) | -€11.86m |
| Revenue (TTM) | €718.26k |
254.6x
P/S Ratio-15.4x
P/E RatioIs 88Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 88Q income statement (TTM) | |
|---|---|
| Revenue | UK£596.00k |
| Cost of Revenue | UK£181.00k |
| Gross Profit | UK£415.00k |
| Other Expenses | UK£10.25m |
| Earnings | -UK£9.84m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.77 |
| Gross Margin | 69.63% |
| Net Profit Margin | -1,650.67% |
| Debt/Equity Ratio | -296.9% |
How did 88Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 05:26 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
4basebio PLC is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pierre Sylvain Rousseau | Barclays |
| Andrew Murray Darley | Cavendish |
| Mark Brewer | Cavendish |